ALPCO to Launch New Zonulin ELISAs and Therapeutic Drug Monitoring

Assays for IBD at Digestive Disease Week

ALPCO will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive
Disease Week May 7-9, 2017 in Chicago, IL. Included in this launch are two Zonulin ELISAs for
the study of gut permeability and celiac disease, as well as therapeutic drug monitoring assays for
IBD.

Salem, NH, May 02, 2017 --(PR.com)-- ALPCO, a leading producer of research and clinical
immunoassays, announced it will launch new gastrointestinal and inflammatory bowel disease (IBD)
assays at Digestive Disease Week May 7-9, 2017 in Chicago, IL. Included in this release are the
Zonulin Stool ELISA and Zonulin Serum ELISA to aid in the study of gut permeability and celiac
disease. Both assays specifically quantify levels of zonulin with no cross-reactivity to haptoglobin 1 or 2.
These new zonulin ELISAs expand ALPCO's current gastrointestinal assay panel to investigate bile acids,
calprotectin, alpha-1 antitrypsin, lysozyme, secretory IgA and pancreatic elastase.

ALPCO will also introduce its therapeutic drug monitoring assay portfolio. Therapeutic drug monitoring
of biologics and antibodies against biologics in IBD can provide significant information in determining
the appropriate dose. ALPCO's therapeutic drug monitoring panel includes ELISAs for testing response
to the commonly used biologics adalimumab, infliximab, golimumab, and vedolizumab. These ELISAs
are Health Canada Licensed, however remain for Research Use Only in the United States.

When asked why the company chose to launch these products at Digestive Disease Week, ALPCO
President Sean Conley explained, This meeting hosts physicians, researchers, and academics in the
gastroenterology field who, like us, share the common goal of advancing research to help improve patient
outcomes. As such, we felt this was the best arena for us to showcase new product offerings that can not
only aid in gastroenterology research, but also eventually improve the quality of care that healthcare
professionals can provide to their IBD patients.

To learn more, visit ALPCO in booth 2211 at Digestive Disease Week, or visit www.alpco.com.

About ALPCO
American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of
immunoassay-based products for the North American life science markets. The company has since grown
into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO
offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools
for advancing research and improving quality of care.

Digestive Disease Week and DDW are registered trademarks of the DDW LLC.

Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
ALPCO
Bethany Bell, PhD
1-800-592-5726
Contact via Email
www.alpco.com

Online Version of Press Release:

You can read the online version of this press release at: http://www.pr.com/press-release/714752

News Image:

Page 2/2
PR.com Press Release Distribution Terms of Use